This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Blood Viscosity, End-Stage Renal Disease, And Mortality (BEAM-1) (BEAM-1)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2009 by ProMetrics, Inc..
Recruitment status was:  Enrolling by invitation
Information provided by:
ProMetrics, Inc. Identifier:
First received: December 1, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted
Prospective, real-time observational study of hemodialysis patients treated with erythropoiesis-stimulating agents (ESA) to currently recommended Hgb targets. Subjects will be evaluated dynamically for their blood viscosity status at the beginning and end of the dialysis treatment, and followed prospectively to assess outcomes. Blood specimens will be collected via the subject's hemodialysis port pre- and post-hemodialysis per study assessment visit. Blood will be analyzed at a designated laboratory facility for viscosity over a comprehensive range of shear rates and tested for intradialytic surges in blood viscosity. Subjects will be followed for 48 weeks.

Renal Replacement Therapy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Clinical Diagnostic Evaluation Study of Blood Viscosity, End-Stage Renal Disease, And Mortality

Resource links provided by NLM:

Further study details as provided by ProMetrics, Inc.:

Primary Outcome Measures:
  • Cardiovascular mortality [ Time Frame: One year ]

Secondary Outcome Measures:
  • All-cause mortality [ Time Frame: One year ]
  • Vascular access thrombosis [ Time Frame: One year ]

Estimated Enrollment: 400
Study Start Date: November 2009
Estimated Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
End-stage renal disease


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Dialysis clinic

Inclusion Criteria:

  • Age > 18 years old
  • On hemodialysis > 3 months
  • On ESA treatment > 3 months
  • Mean Hgb 11 g/dL - 12 g/dL (based on at least 3 Hgb results during the previous 8 weeks)
  • Latest Hgb 10.5 g/dL - 12.5 g/dL (measured within 1 week of study)

Exclusion Criteria:

  • Inability or unwillingness to provide informed consent
  • Large variability in interdialytic weight gain (>2 kg difference between low and high weight gain over last month)
  • More than 1 missed dialysis treatments in past month
  • Recent bleeding
  • Blood transfusion within 1 month
  • Hematologic disease other than anemia
  • Active inflammatory disease
  • Active infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Daniel Cho, VP Lab Services, ProMetrics Identifier: NCT01023893     History of Changes
Other Study ID Numbers: PRO-0062-201
Study First Received: December 1, 2009
Last Updated: December 1, 2009

Additional relevant MeSH terms:
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency processed this record on August 18, 2017